An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer’s disease

The conversion of the β-amyloid (Aβ) peptide into pathogenic aggregates is linked to the onset and progression of Alzheimer’s disease. Although this observation has prompted an extensive search for therapeutic agents to modulate the concentration of Aβ or inhibit its aggregation, all clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Habchi, Johnny, Arosio, Paolo, Perni, Michele, Costa, Ana Rita, Yagi-Utsumi, Maho, Joshi, Priyanka, Chia, Sean, Cohen, Samuel I. A., Müller, Martin B. D., Linse, Sara, Nollen, Ellen A. A., Dobson, Christopher M., Knowles, Tuomas P. J., Vendruscolo, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758743/
https://www.ncbi.nlm.nih.gov/pubmed/26933687
http://dx.doi.org/10.1126/sciadv.1501244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758743/
https://www.ncbi.nlm.nih.gov/pubmed/26933687
http://dx.doi.org/10.1126/sciadv.1501244

Ejemplares similares